Wolff, Lennard http://orcid.org/0000-0002-2448-122X
Uniken Venema, Simone M.
Luijten, Sven P. R.
Hofmeijer, Jeannette
Martens, Jasper M.
Bernsen, Marie Louise E.
van Es, Adriaan C. G. M.
van Doormaal, Pieter Jan
Dippel, Diederik W. J.
van Zwam, Wim
van Walsum, Theo
van der Lugt, Aad
,
Funding for this research was provided by:
TWIN
Amsterdam UMC
Erasmus Medisch Centrum
Maastricht Universitair Medisch Centrum
Netherlands Cardiovascular Research Initiative
Hersenstichting
Stryker
penumbra
Medtronic
ceronovus
Article History
Received: 11 October 2021
Revised: 24 December 2021
Accepted: 29 January 2022
First Online: 4 March 2022
Declarations
:
: The scientific guarantor of this publication is Aad van der Lugt.
: The authors of this manuscript declare relationships with the following companies.Lennard Wolff: noneSimone M. Uniken Venema: noneSven P.R. Luijten: noneJeannette Hofmeijer: noneJasper M. Martens: noneMarie Louise E. Bernsen:Pieter Jan van Doormaal: noneAdriaan C.G.M. van Es: noneDiederik W.J. Dippel: noneWim van Zwam: The Maastricht UMC+ received funds for consultations done by WHZ for Cerenovus and Stryker Neurovascular.Theo van Walsum: noneAad van der Lugt: The Erasmus MC received grants for research from Siemens Healthineers, GE Healthcare, and Philips Healthcare.
: No complex statistical methods were necessary for this paper.
: Written informed consent was obtained from all subjects (patients) or their legal representatives in this study.
: Institutional Review Board approval was obtained.
: Some study subjects or cohorts have been previously reported in other MR CLEAN Registry publications.
: • retrospective (this study)• randomized, controlled, open-label, phase 3 trial• multicenter study